Business Wire

Ascom Myco smarttelefon for helsesektoren er nå kompatibel med Ekahau RTLS

Del

Ascom Wireless Solutions og Ekahau, en ledende leverandør av sanntidslokaliseringssystemer (RTLS), kunngjør at Ascom Myco smarttelefon nå er kompatibel med Ekahau RTLS. Ascom Myco er markedets første smarttelefon spesialdesignet til helsesektoren. Det er et avansert informasjonssystem som gir fleksibilitet, holdbarhet og praktisk nytte i et og samme håndsett. Ascom Myco er designet spesielt for pleiepersonale, og brukerne kan nå få glede av Ekahau RTLS-lokaliseringsfunksjonalitet.

RFID-over-Wi-Fi™ er en proprietær teknologi fra Ekahau som sender data om hvor personer og utstyr befinner seg. Dataene kan gi f.eks. sykehus viktig informasjon i sanntid. Ekahau RTLS-løsninger er alltid operative og benyttes av noen av verdens største helseinstitusjoner – hvorav mange også benytter Ascom-løsninger. Lokalitseringsdata kan gi besparelser og forbedre pleien. "Vårt felles mål er å hjelpe pleiepersonale med å bli mer effektive, og i den forstand fungerer Ekahau og Ascoms Wi-Fi-baserte løsninger meget godt sammen," sier Ekahaus administrerende direktør, Michel Wendell. "IoE ("The Internet of Everything") er over oss, og nå kan sykepleiere over alt føle større trygghet med én enhet som er aktivert for lokalisering".

For Henrik Sandberg, Alliances Manager hos Ascom Wireless Solutions, stadfester kompatibiliteten med Ekahau RTLS Ascom Mycos evne til å støtte en lang rekke applikasjoner og funksjoner til helsesektoren. "Denne brede formen for støtte bidrar til at Ascom Myco er pleiepersonalets foretrukne løsning", sier Sandberg. Alarmer, anrop, pasientdata og nå personalarmer med RTLS, nesten alle de tidskritiske data som pleierne har bruk for, er nå tilgjengelig i ett håndsett som er spesialdesignet til helesektoren."

For mer informasjon om Ascom Myco, besøk www.ascommyco.com For mer informasjon om Ekahau RTLS, besøk www.ekahau.com/rtls.com Eksisterende Ascom-brukere kan oppgradere til Ascom Myco og aktivere Ekahau RTLS ved å kontakte deres Ascom-forhandler eller Ekahau direkte på 866-4-EKAHAU.

For mer informasjon, besøk www.ascom.com/ws

OM ASCOM WIRELESS SOLUTIONS

Ascom Wireless Solutions (www.ascom.com/ws) er en ledende leverandør av innovative kommunikasjonsløsninger for integrerte arbeidsprosesser for segmenter som sykehus, eldreomsorg, samt på andre områder der virksomhetskritisk kommunikasjon er viktig. Ca. 100 000 systemer er installert globalt. Selskapet tilbyr et bredt utvalg profesjonelle telefoni- og meldingssystemer, og genererer verdi for kundene ved å støtte og optimere deres virksomhetskritiske prosesser. Løsningene er basert på mobil, VoWiFi, IP-DECT, pasientsignal og personsøkerteknologi som integreres på en smart måte i eksisterende virksomhetssystemer. Selskapet har datterselskaper i 13 land og 1200 ansatte globalt. Firmaet ble grunnlagt i Göteborg i 1955 og er en del av Ascom Group som er børsnotert på Swiss Stock Exchange (ASCN:SIX).

OM EKAHAU

Ekahau er en ledende leverandør av Wi-Fi-basert RTLS og planløsninger for Wi-Fi-nettverksoptimalisering. Med innovative produkter og patentert teknologi leverer Ekahau overlegne løsninger til organisasjoner som ønsker bedre business intelligence og driftssikkerhet, for å lykkes bedre med deres virksomhet. Fra kapitalforvaltning og medarbeidersikkerhet til temperaturovervåking, gir Ekahau RTLS lokaliseringsklarhet til hele helseinstitusjonen. Ekahaus løsninger brukes av Fortune 500-selskaper og mer enn 300 sykehus, samt en rekke internasjonale selskaper innenfor sektorer som produksjon, butikk, industri, offentlighet og det militære. Ekahaus partnere inkluderer utviklere av trådløse programvarer, ledende systemintegratorer og internasjonale OEM-partnere, som utvikler og markedsfører trådløse bedriftsapplikasjoner.

Contact information

Ascom Wireless Solutions
Henrik Sandberg
Tlf.: +46 703 533 578
E-postadresse: Henrik.Sandberg@ascom.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i